Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelimumab plus bevacizumab as postoperative adjuvant therapy for high-risk hepatocellular carcinoma
ChiCTR2300077544Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Recurrence-free survival rate. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
adebrelimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300077544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077544.